FDA's final and draft nanotechnology guidance documents: No big surprises

被引：0

|

作者：

机构：

来源：

Nanotechnol. Law Bus. | / 1卷 / 54-58期

关键词：

761; Nanotechnology;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

收藏

相关论文

共 50 条

[31] FDA Releases Draft Guidance on Regulation of Genetically Engineered Animals
Gluck, John P.
Holdsworth, Mark T.
KENNEDY INSTITUTE OF ETHICS JOURNAL, 2008, 18 (04) : 393 - 402
[32] Meeting on the FDA draft guidance on patient-reported outcomes
Dueck, Amylou C.
Sloan, Jeff A.
VALUE IN HEALTH, 2007, 10 : S64 - S65
[33] US FDA issues draft guidance on shared REMS for generics
Reactions Weekly, 2017, 1679 (1) : 3 - 3
[34] Introduction to Discussion Papers on Draft FDA Guidance on Adaptive Designs
Chang, Mark
JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2010, 20 (06) : 1113 - 1114
[35] US FDA issues draft guidance on currently unapproved medicines
Reactions Weekly, 2003, 974 (1) : 3 - 3
[36] Interchangeability Of Biological Drug Products-FDA Draft Guidance
Endrenyi, Laszlo
Markus, Richard
JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2019, 29 (06) : 1003 - 1010
[37] Adverse reactions with HCT/Ps: FDA issues draft guidance
Reactions Weekly, 2015, 1541 (1) : 1 - 1
[38] Some statistical considerations on the FDA draft guidance for individual bioequivalence
Hsuan, FC
STATISTICS IN MEDICINE, 2000, 19 (20) : 2879 - 2884
[39] Final FDA guidance on abuse-deterrent opioids
Reactions Weekly, 2015, 1547 (1) : 1 - 1
[40] Updated US FDA draft guidance: ICH S9 nonclinical evaluation for oncotherapeutics
不详
BIOANALYSIS, 2009, 1 (02) : 271 - 271

← 1 2 3 4 5 →